The tumor suppressor gene KCTD11REN is regulated by Sp1 and methylation and its expression is reduced in tumors

A hallmark of several human cancers is loss of heterozygosity (LOH) of chromosome 17p13. The same chromosomal region is also frequently hypermethylated in cancer. Although loss of 17p13 has been often associated with p53 genetic alteration or Hypermethylated in Cancer 1 (HIC1) gene hypermethylation, other tumor suppressor genes (TSGs) located in this region have critical roles in tumorigenesis. A novel TSG mapping on human chromosome 17p13.2 is KCTD11REN (KCTD11). We have recently demonstrated that KCTD11 expression is frequently lost in human medulloblastoma (MB), in part by LOH and in part by uncharacterized epigenetic events. Using a panel of human 177 tumor samples and their normal matching samples representing 18 different types of cancer, we show here that the down-regulation of KCTD11 protein level is a specific and a diffusely common event in tumorigenesis. Additionally, in order to characterize the regulatory regions in KCTD11 promoter, we identified a CpG island and several Sp1 binding sites on this promoter, and demonstrated that Sp1 transcription factor and DNA methylation contribute, at least in part, to regulate KCTD11 expression. Our findings identify KCTD11 as a widely down-regulated gene in human cancers, and provide a basis to understand how its expression might be deregulated in tumor cells.


Findings
TSGs often locate at chromosomal regions, which are frequently deleted and/or methylated in tumors. High levels of 17p13 somatic alterations have been showed in several tumors, distal and independent of the p53 locus [1][2][3][4].
Our group has identified KCTD11 as an immediateearly gene induced by neurogenic signals [5] and encoding a novel adaptor of Cullin3 ubiquitin E3 ligase complex targeting Histone Deacetylase 1 [6]. Importantly, KCTD11 is a novel TSG that inhibits cell growth and is mapping on human chromosome 17p13.2, whose expression is frequently lost in human MB [4].
To analyze whether the down-regulation of KCTD11 represents a specific feature of MB, as well to other cancers, we performed a wide screening for KCTD11 expression, analyzing 177 human tumor samples and 177 normal matching samples, representing 18 different cancer types. Normal tissues, including larynx, esophagus, stomach, colon-rectum, urinary bladder, lung, breast, gallbladder and endometrium, exhibited a nuclear KCTD11 positive immunohistochemical staining between 40 to 78% (Fig. 1B), whereas the matching tumor samples showed a significant reduction of 0 to 18% of nuclear KCTD11 staining ( Fig. 1A and 1B). Reduced KCTD11 expression was not observed in thyroid and kidney tumor tissues vs normal suggesting a tumorigenic specific role of KCTD11 for the above mentioned tissues (Fig. 1A and 1B and data not shown). Moreover KCTD11 was undetected both in normal and cancer tissues from liver, lymph-node and exocrine pancreas (data not shown). Together, these findings clearly indicated that selective tissues expressing KCTD11 have down-regulated this gene during tumorigenesis.
To understand the transcriptional regulation of KCTD11, we identified and analyzed the promoter region. Human KCTD11 proximal promoter is a 623 bp region ( Fig. 2A). It turned out to be a TATA-and CAAT-less promoter. The transcription start site (TSS) was previously identified [4] (Fig. 2A). Using the TRANSFACT software, we identified six putative binding sites for Sp1 transcription factor (TF), two of them located closely to the TSS (see Fig. 2A, Sp1-E and Sp1-F). Sp1 is a well-characterized transcriptional activator [7,8]. It is essential for proper expression of a large variety of genes involved in development, cell growth regulation and cancer [9,10]. Moreover, Sp1 is responsible for recruiting TATA-binding protein and fixing the TSS at TATAless promoters [9,11]. Thus, the Sp1-E and Sp1-F binding sites on KCTD11 promoter ( Fig. 2A) are likely to be responsible for assembling of the basal transcription complex. , lung (c, d), stomach (e, f), colon-rectum (g, h), urinary bladder (i, j) and thyroid (k, l) (40x magnification). Tissue arrays (Super Bio Chips; cat. n. MA, MAN, MB, MBN, MC, MCN; http://www.tissue-array.com/ver3/index.php) were incubated with 1 mg/ml affinity-purified rabbit polyclonal anti-KCTD11 antibody, as previously described [12]. (B) Graphic representation of KCTD11 IHC analysis of tissue arrays. Normal and cancer tissues were analyzed counting nuclear staining as percent point. 10 high power fields (hps 40x) were counted for each sample. Stromal and inflammatory cells were not selected for nuclear staining counting. The significance of differences between normal (N) and tumor (T) tissues means was estimated using Student's t-test. (* indicates p < 0.005; ** indicates p < 0.001). Larinx: N n = 5, T n = 7; Esophagus: N n = 9, T n = 10; Stomach: N n = 13, T n = 10; Colon-rectum: N n = 12, T n = 10; Urinary bladder: N n = 5, T n = 9; Lung: N n = 10, T n = 10; Breast: N n = 4, T n = 10; Gallbladder: N n = 8, T n = 6; Endometrium: N n = 7, T n = 10; Thyroid: N n = 10, T n = 10. n: number of cases for each group. To understand the regulation of KCTD11 promoter by Sp1, we analyzed the transcriptional activity of fulllength and various deleted forms of KCTD11 promoter ( Fig. 2B-D). Surprisingly, full-length KCTD11 promoter showed a strong basal transcriptional activity (see Fig.  2C, -522/+99), as the luciferase activity was 2.5 folds higher than that of pGL3-promoter, containing the strong SV40 promoter. Although slightly decreased, KCTD11 promoter activity was not drastically dropped down by deletion of the Sp1-A, Sp1-B, Sp1-C and Sp1-D sites, whereas it resulted strongly dependent on Sp1-E and Sp1-F sites ( Fig. 2B-C). Importantly, the interval between Sp1-B and Sp1-C sites is too short to allow Sp1 to bind both sites, and this might explain why -398/+99 (containing Sp1-B and Sp1-C) and -338/+99 (lacking Sp1-B) mutants showed the same transactivation ability. Similar results have been obtained by transfecting KCTD11 promoter constructs in other cell lines [additional file 1]. To verify the importance of Sp1-E and Sp1-F binding sites for KCTD11 promoter activity, a full-length KCTD11 promoter construct bearing a deletion -156/-38 -the region containing the Sp1-E and Sp1-F -was generated (Fig. 2B, -522/-157Δ-37/+99). The deletion of Sp1-E and Sp1-F sites strongly affected the ability of KCTD11 promoter to drive transcription (Fig. 2D, compare -522/-157Δ-37/+99 to -522/+99). Most likely, Sp1 binds only to one of these two sites, considering the short interval between Sp1-E and Sp1-F sites. To exclude that the Sp1-E upstream region -156/-82, which was also deleted in the -522/-157Δ-37/+99 construct, was relevant to the promoter activity, we further generated and tested an -81/+99 construct (Fig.  2B), demonstrating that this region did not have any effect on KCTD11 transcriptional activity (Fig. 2D, compare -156/+99 and -81/+99).
Finally, we assessed the in vivo relevance of Sp1mediated regulation of KCTD11 gene, performing ChIP-qPCR for Sp1, Sp3 and Acetyl-H3 on ARO cells (a thyroid cancer cell line, matching a tumor tissue sample in which KCTD11 is expressed; see Fig. 1) and HCT15 cells (a colon cancer cell line, matching a cancer type in which KCTD11 is inhibited; see Fig. 1). As shown in Fig. 3C, Sp1 binds to KCTD11 promoter much strongly in ARO cells than in HCT15 cells, confirming that Sp1 plays a pivotal role in regulating KCTD11 gene expression, in vivo. At contrary, ARO and HCT15 cell lines showed no differences in Sp3 binding to KCTD11 promoter. Importantly, Acetyl-H3 binds to KCTD11 promoter much strongly in ARO cells than in HCT15 cells, indicating that this promoter is more acetylated in ARO cells than in HCT15 cells.
These data demonstrated that Sp1 TF is necessary for the basal transcriptional activity of KCTD11 TATA-less promoter.
The Sp-regulated promoters are often associated with GC-rich regions of the genome known as CpG islands, which are important for gene regulation [12]. The presence of six Sp1 binding sites on KCTD11 promoter and the mapping of human KCTD11 at the highly methylated chromosomal region 17p13 prompted us to investigate the involvement of DNA methylation in KCTD11 regulation.
We found a putative CpG island overlapping almost all KCTD11 promoter (-522 to +70), which contains 72 CpG dinucleotides ( Fig. 2A; 4A). To evaluate whether methylation might regulate KCTD11 transcription, we investigated the effects of demethylation on KCTD11 expression, in two human colon cancer cell lines, HCT15 and HCT116. 5′-Aza-2′-deoxycytidine (Aza) treatment of these cells significantly increased KCTD11 mRNA level (Fig. 4B). It is worth to note that the induction of KCTD11 expression that we observed here with were co-transfected along with 1 μg of pPac empty vector, pPac-Sp1 or pPac-Sp2 (left panel) or pPac-Sp3 and pPac-Sp1+pPac-Sp3 (right panel) using Cellfectin (Invitrogen). After 48 h, the cells were harvested and the luciferase activity was assayed using the Single Luciferase Assay System (Promega), normalized to β-galactosidase activity using β-Galactosidase Enzyme Assay System (Promega). Each experiment has been done in triplicates. Values are the means ± S.D. (B) EMSAs showing the binding of Sp1 to KCTD11 promoter. Whole extracts were prepared from 293T HEK cells transfected with pCDNA-Sp1 (12 μg), using buffer C [16]. Cell extracts were incubated in vitro with 32 P-labeled KCTD11-Sp1 probes (Sp1-A-F) or 32 P-labeled canonical Sp1 probe [additional file 2]. Binding specificity was evaluated by competition with an excess (100x) of the cold probe or with a non-specific probe. For the supershift assays, the proteins were pre-incubated with two different anti-Sp1 antibodies (Santa-Cruz) at 4°C for 30 min. (C) ARO (thyroid cancer) and HCT15 (colon cancer) cell line were cultured, respectively, in RPMI-1640 and DMEM supplemented with 10% FCS. Chromatin Immunoprecipitations (ChIP) were performed by using the following antibodies: anti-Sp1 (1C6) X (sc-420; Santa Cruz Biotech), anti-Sp3 (F-7) X (sc-28305; Santa Cruz Biotech), anti-Acetyl-Histone3 (Cell Signaling). Eluted DNA has been analyzed with real-time q-PCR, normalized to GAPDH (left panels). Bars represent the mean of 3 independent experiments ± SD (*, p < 0.05, HCT15 versus ARO). Total protein levels of Sp1 and Sp3 were analyzed by Western blot (right panel).
Aza is comparable with the induction by RA, NGF and EGF or during differentiation of cultured cerebellar GCPs observed in previous studies and there considered physiologically relevant [5,13]. We therefore investigated the methylation profile of KCTD11 promoter in HCT15 and HCT116 cell lines. DNAs from sodium bisulfitetreated HCT116 and HCT15 were amplified by PCR, subcloned and sequenced. Sequences showed that KCTD11 promoter is methylated in both HCT-15 and HCT-116 cell lines with a similar pattern (Fig. 4C). As control, DNAs from Aza and sodium bisulfite-treated HCT116 and HCT15 cells showed, as expected, C-T conversion of all cytosines (not shown). Together, these data clearly demonstrate a direct role of the methylation on KCTD11 transcriptional activity. Interestingly the regions of KCTD11 promoter resulting methylated are located mainly in the 5′ region (Fig. 4C), in particular the region upstream of Sp1-A binding site (-517/-501 meaning CpGs 2 to 4), the region in between of Sp1-A and Sp1-C binding sites (-443/-331 meaning CpGs 8 to 24) and the region upstream of Sp1-D binding site (-279/-278 meaning CpG 30) ( Fig. 2A, 4C).
Thus, the majority of the methylated CpGs in KCTD11 promoter are not located at Sp1 binding sites, but in the surrounding regions. To this regard, published reports have implicated Sp1 binding sites involved in the maintenance of the methylation-free status of the CpG islands [12,14,15]. Thus, the balance between DNA methylation and Sp1 binding to the promoter may represent a mechanism to regulate the tissue-specific expression pattern of KCTD11. It is noteworthy that the chromosomal region 17p13, where KCTD11 localized, is frequently hypermethylated in cancer. Therefore, the strong down-regulation of KCTD11 in cancers (Fig. 1) may be due to promoter hypermethylation. Of course, we cannot exclude that other mechanisms might play a role in the physio-pathological regulation of KCTD11 expression, such as inhibition of Sp1 activity by other proteins. In summary, we reported a dramatic downexpression of KCTD11 protein in several types of cancer. Importantly, we identified a CpG island and several Sp1 binding sites in the KCTD11 promoter region and further demonstrated that Sp1 transcription factor and DNA methylation contributed, at least in part, to regulate KCTD11 expression. These findings provide a basis to implicate that decreased expression of KCTD11 tumor suppressor gene is associated with cancers of specific tissue types.

Additional material
Additional file 1: KCTD11 transcriptional activity in D283, TSU and HCT116 cell lines is comparable to the 293T KCTD11 transcriptional activity. Luciferase assays showing the transcriptional activity of fulllength or deletion mutants of KCTD11 promoter. D283 (medulloblastoma cell line) was cultured in Eagle's Minimum Essential Medium and TSU (prostate carcinoma cell line) was cultured in RPMI-1640 supplemented with 10% FCS, 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Sigma); HCT116 was cultured as previously described in Figure 4. 2 μg of KCTD11-Luc reporter constructs were transfected using Lipofectamine 2000 (Invitrogen). After 24 hrs, the cells were harvested and firefly luciferase activity was assayed using the Firelite Dual Luminescence Reporter Gene Assay System kit (Perkin-Elmer) normalized to Renilla luciferase activity. Each experiment has been done in triplicates. Values are the means ± S.D.
Additional file 2: Table -Primer sequences for cloning KCTD11 promoter constructs, for q-PCR, for EMSA Sp1 canonic and Sp1-KCTD11 promoter probes, for CHIP-q-PCR and for methylation study.